UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 31ST MARCH, 2007
PARTICULARS
Nine months
Ended 31.12.06
Unaudited
Three months
Ended 31.03.07
Unaudited
Three Months
Ended 31.03.06
Audited
Year ended
31.03.07
Unaudited
Year ended
31.03.06
Audited
Net Sales/Other Income
22559.9
13237.29
8086.42
35797.2
32445.03
TOTAL EXPENDITURE :
18303.41
11374.46
6668.93
29677.87
26300.61
(a) (Increase)/decrease in stock in trade
(761.50)
(73.86)
(716.78)
(835.36)
(1595.27)
(b) Consumption of Raw Material
14178.53
9815.55
5868.84
23994.08
22070.92
(c) Staff Cost
624.78
263.57
160.26
888.36
640.02
(d) Other expenditure
4261.61
1369.19
1356.62
5630.80
5184.93
Interest
1630.47
682.05
429.75
2312.52
1245.20
Depreciation
880.51
382.05
228.14
1262.57
810.88
Profit before tax
1745.52
798.73
759.60
2544.24
4088.34
Provision for taxation
220.60
99.52
81.03
320.13
361.14
Provision for fringe benefit tax
7.48
6.56
1.83
14.05
6.38
Net Profit before Deferred Tax
1517.43
692.64
676.73
2210.07
3720.82
Provision for deferred tax
92.17
26.54
(60.10)
118.71
242.14
Net Profit
1425.25
666.10
736.84
2091.35
3478.68
Paid up Equity Share Capital
2250.10
2283.60
2152.00
Reserve excluding revaluation
reserves
19234.72
20101.82
16810.23
EPS Rs. (Not Annualized) Basic
6.45
3.00
3.71
9.42
17.52
Diluted
6.45
2.97
3.61
9.31
17.00
Aggregated on Non-Promoters
Shareholding
No. of Shares
15704594
15704594
15504594
% of Shareholding
69.80%
68.77%
72.05%
Notes:
1
The Company has filed 36 Patents for its products
and one patent for Cardiovascular Drug has been granted.
2
The Company is in the process of introducing 10 new Products. Out of these 5 products
will be introduced in the Domestic Market.
3
The Company facilities for Microlide Antibiotic has been successfully
inspected during quarter by USFDA Authority.
4
During the quarter the Company has allotted 28,00,000
Optionally convertible warrants to Promoter Group Companies at
price of Rs.70/- per warrant. Out of these 3,35,000 warrants were converted into
equity share during the quarter.. The utilization of proceeds arising
from the issue of warrant / shares is as under:
Rs.
in lacs.
a) Derabassi facility expansion including capital advances 292.05
b) Short Term Deployment in Working Capital for Interest Savings 115.00
Total 407.05
5
Information on Investor Complaints for the quarter: Opening Balance NIL, Received
6, Redressed 6, closing Balance NIL.
6
The previous period figures have been re-grouped and re-arranged wherever necessary.
7
The Company is exclusively in the Pharmaceutical business segment.
8
The above results were taken on record by the Board of Directors in its meeting
held on 30th April, 2007.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date: 30th April, 2007
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other
group company.
